Top

Cancer Chemotherapy and Pharmacology

Published in:

01-05-2012 | Original Article

Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index

Authors: Thea Eline Hetland, Janne Kærn, Martina Skrede, Berit Sandstad, Claes Tropé, Ben Davidson, Vivi Ann Flørenes

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2012

Abstract

Purpose

We aimed to identify primary platinum resistance in epithelial ovarian cancer (OC) patients with FIGO stage III–IV disease by an in vitro drug-response assay and to correlate the findings with clinical response. We considered whether neoadjuvant chemotherapy or anatomic sample site and tumor heterogeneity would influence the results.

Methods

We combined the ATP-based tumor-chemosensitivity and the extreme drug resistance assays for testing of 85 biopsies from 58 patients. Tumors were classified as sensitive or resistant by a resistance index (RI). We did separate analyses of primary tumors and metastases and compared chemo-naïve samples with samples obtained after neoadjuvant chemotherapy. Results were analyzed for association with clinical platinum resistance, progression-free survival (PFS), and overall survival (OS).

Results

RI ≤ 250 predicted primary platinum resistance, without misclassification of sensitive patients. The test sensitivity for primary tumors was 15/15, specificity 3/10, negative predictive value 3/3, and positive predictive value 15/22. Patients with in vitro platinum-resistant samples had shorter PFS compared with patients with sensitive samples (3.4 vs. 10.0 months, p = 0.02). Comparing patient-matched primary and metastatic samples, there was about 1/3 mismatch in resistance. RI for platinum was lower in primary tumors exposed to neoadjuvant chemotherapy than in chemo-naïve tumors (p < 0.01).

Conclusions

This in vitro assay predicted primary platinum resistance, without misclassification of sensitive OC patients, and the results were significantly associated with PFS. We suggest that samples from primary tumor and metastatic samples have different responses to chemotherapy and that exposure to chemotherapy might induce in vitro platinum resistance.

Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HY, Pecorelli S (2003) Carcinoma of the ovary. Int J Gynaecol Obstet 83(Suppl 1):135–166PubMedCrossRef

Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351:2519–2529PubMedCrossRef

Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analyses. J Clin Oncol 20:1248–1259PubMedCrossRef

Vergote I, Trope CG, Amant F et al (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363:943–953PubMedCrossRef

Salom E, Almeida Z, Mirhashemi R (2002) Management of recurrent ovarian cancer: evidence-based decisions. Curr Opin Oncol 14:519–527PubMedCrossRef

Markman M, Bookman MA (2000) Second-line treatment of ovarian cancer. Oncologist 5:26–35PubMedCrossRef

Pujade-Lauraine E, Mahner S, Kaern J et al (2009) A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the gynecologic cancer intergroup (GCIG). J Clin Oncol 27:No 18s

Harter P, Hilpert F, Mahner S, Heitz F, Pfisterer J, du Bois A (2010) Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs. Expert Rev Anticancer Ther 10:81–88PubMedCrossRef

Cree IA (2009) Chemosensitivity and chemoresistance testing in ovarian cancer. Curr Opin Obstet Gynecol 21:39–43PubMedCrossRef

10.

Andreotti PE, Cree IA, Kurbacher CM et al (1995) Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 55:5276–5282PubMed

11.

Cree IA, Kurbacher CM, Lamont A, Hindley AC, Love S, Ovarian Cancer Trial Group TCA (2007) A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician’s choice in patients with recurrent platinum-resistant ovarian cancer. Anticancer Drugs 18:1093–1101PubMedCrossRef

12.

Kim HS, Kim TJ, Chung HH, Kim JW, Kim BG, Park NH, Song YS, Bae DS, Kang SB (2009) In vitro extreme drug resistance assay to taxanes or platinum compounds for the prediction of clinical outcomes in epithelial ovarian cancer: a prospective cohort study. J Cancer Res Clin Oncol 135:1513–1520PubMedCrossRef

13.

Konecny G, Crohns C, Pegram M, Felber M, Lude S, Kurbacher C, Cree IA, Hepp H, Untch M (2000) Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer. Gynecol Oncol 77:258–263PubMedCrossRef

14.

Loizzi V, Chan JK, Osann K, Cappuccini F, DiSaia PJ, Berman ML (2003) Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy. Am J Obstet Gynecol 189:1301–1307PubMedCrossRef

15.

Sharma S, Neale MH, Di Nicolantonio F et al (2003) Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma. BMC Cancer 3:19PubMedCrossRef

16.

Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ (1994) Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 12:1748–1753PubMed

17.

Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRef

18.

Holloway RW, Mehta RS, Finkler NJ, Li KT, McLaren CE, Parker RJ, Fruehauf JP (2002) Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol Oncol 87:8–16PubMedCrossRef

19.

Neubauer H, Stefanova M, Solomayer E, Meisner C, Zwirner M, Wallwiener D, Fehm T (2008) Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer. Anticancer Res 28:949–955PubMed

20.

Kaern J, Trope CG, Kristensen GB, Pettersen EO (1994) Flow cytometric DNA ploidy and S-phase heterogeneity in advanced ovarian carcinoma. Cancer 73:1870–1877PubMedCrossRef

21.

Bertelsen CA, Korn EI, Morton DL, Kern DH (1983) Heterogeneity of human metastatic clones by in vitro chemosensitivity testing. Implications for the clinical application of the clonogenic assay. Arch Surg 118:1406–1409PubMedCrossRef

22.

McAlpine JN, Eisenkop SM, Spirtos NM (2008) Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays. Gynecol Oncol 110:360–364PubMedCrossRef

23.

Tewari KS, Mehta RS, Burger RA et al (2005) Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma. Gynecol Oncol 98:360–368PubMedCrossRef

24.

Matsuo K, Eno ML, Im DD, Rosenshein NB (2010) Chemotherapy time interval and development of platinum and taxane resistance in ovarian, fallopian, and peritoneal carcinomas. Arch Gynecol Obstet 281:325–328PubMedCrossRef

25.

Tiersten AD, Moon J, Smith HO, Wilczynski SP, Robinson WR 3rd, Markman M, Alberts DS (2009) Chemotherapy resistance as a predictor of progression-free survival in ovarian cancer patients treated with neoadjuvant chemotherapy and surgical cytoreduction followed by intraperitoneal chemotherapy: a Southwest Oncology Group Study. Oncology 77:395–399PubMedCrossRef

26.

Cooke SL, Brenton JD (2011) Evolution of platinum resistance in high-grade serous ovarian cancer. Lancet Oncol 12:1169–1174PubMedCrossRef

27.

du Bois A, Harter P (2010) Understanding and optimizing the potential role of surgical debulking in advanced epithelial ovarian cancer. ASGO 2010 Educational Book—Category. Gynecologic cancer: e13–e17

Title: Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index
Authors: Thea Eline Hetland
Janne Kærn
Martina Skrede
Berit Sandstad
Claes Tropé
Ben Davidson
Vivi Ann Flørenes
Publication date: 01-05-2012
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 5/2012
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-012-1835-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2012

Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice

A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer

Gemcitabine in combination with vinorelbine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer

A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer

Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma

Pharmacokinetics and tissue and tumor exposure of CP-31398, a p53-stabilizing agent, in rats

Keynote webinar | Spotlight on antibody–drug conjugates in cancer